Predictive parameters of prostate carcinoma in negative multiparametric prostate magnetic resonance imaging patients
Öz
Purpose: The aim of this study was to evaluate the predictors of prostate cancer and clinically significant prostate cancer in prostate-specific antigen grey zone patients with pre-biopsy negative multiparametric prostate magnetic resonance imaging.
Materials and Methods: The study analyzed data from 227 patients with negative pre-biopsy multiparametric prostate magnetic resonance imaging results. The detection rates of prostate cancer and clinically significant prostate cancer were calculated, and simple and multiple logistic regression were used to evaluate the predictors of prostate cancer and clinically significant prostate cancer.
Results: The overall prostate cancer rate was 18.9% and the clinically significant prostate cancer detection rate was 8.8%. Multivariate analysis revealed that prostate-specific antigen density and abnormal digital rectal examination were the independent predictive factors for prostate carcinoma, while age and abnormal digital rectal examination were the independent predictive factors for clinically significant prostate carcinoma. Prostate-specific antigen density with the cutoff value of > 0,12 ng/ml/cc had the highest area under curve values for clinically significant prostate carcinoma followed by prostate volume with a cutoff value of ≤ 46 cc.
Conclusion: Based on the findings of the study, the cutoff value of prostate-specific antigen density of > 0,12 ng/ml/cc and prostate volume ≤ 46 cc might be considered for biopsy decision in grey zone patients regardless of multiparametric prostate magnetic resonance results. However, further studies with larger cohorts are required to validate these recommendations.
Anahtar Kelimeler
prostate biopsy, prostate carcinoma, prostate specific antgen density, prostate volume
Destekleyen Kurum
N/A
Etik Beyan
ALREADY LOADED
Teşekkür
N/A
Kaynakça
- EAU Guidelines on prostate cancer – Uroweb. In: Uroweb – European Association of Urology. https://uroweb.org/guidelines/prostate-cancer. Accessed 14 Apr 2023.
- Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 201725;389:815-22.
- Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F et al; MRI-FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100-09.
- Drost FH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ et al. Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: Cochrane systematic review and meta-analysis. Eur Urol. 2020;77:78-94.
- Barentsz JO, Weinreb JC, Verma S, Thoeny HC, Tempany CM, Shtern F et al. Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol. 2016;69:41-9.
- Wang RS, Kim EH, Vetter JM, Fowler KJ, Shetty AS, Mintz AJ et al. Determination of the role of negative magnetic resonance imaging of the prostate in clinical practice: is biopsy still necessary? Urology. 2017;102:190-7.
- Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M et al. Negative multiparametric magnetic resonance imaging of the prostate predicts absence of clinically significant prostate cancer on 12-core template prostate biopsy. Urology. 2017;105:118-22.
- Schoots IG, Padhani AR, Rouvière O, Barentsz JO, Richenberg J. Analysis of magnetic resonance imaging-directed biopsy strategies for changing the paradigm of prostate cancer diagnosis. Eur Urol Oncol. 2020;3:32-41.
- Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al; PRECISION study group collaborators. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767-77.
- Coogan CL, Latchamsetty KC, Greenfield J, Corman JM, Lynch B, Porter CR. Increasing the number of biopsy cores improves the concordance of biopsy gleason score to prostatectomy gleason score. BJU Int. 2005;96:324-27.
